Next Phase Newsletter

A corporate venture capital arm of a global science-based company invests in seed and venture stage companies, generally taking less than 25% ownership. While the firm has previously invested from seed through PIPE, the focus is on companies with products in development or early commercialization. Initial allocations typically range from a few hundred thousand dollars up to $5 million, with additional reserves for follow-on rounds. The firm is targeting approximately 5–10 investments in the next 6–9 months, and over 10 additional investments in the next 2 years. The investment scope is global, with a focus on the U.S., Europe, and Israel.

Within biomedical, the firm seeks materials science companies in orthopedics and soft tissue repair. In addition, the firm actively invests in human nutritional health, with a specific emphasis on personalized nutrition and companies developing nutritional products. This includes start-ups with digital or technology-driven models that enable personalization and precision.

The firm values experienced management teams and typically seeks a board seat, aiming to play an active role in portfolio companies. Strategic alignment with the parent company’s businesses is also an important consideration for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An institutional alternative investor dedicated to direct investments in the life sciences has offices in Europe. The firm manages total assets under management to over EUR 1 billion. The firm invests EUR 5–20 million per portfolio company and expects to back approximately 20 companies from the current fund. It typically acts as a lead investor, providing equity capital and assuming a 20-40% ownership stake. While the firm primarily targets companies in Europe, around 30% of its portfolio is allocated to global opportunities. 

The firm invests in Therapeutics and Medical Devices. For therapeutics, the focus is on companies with proof of principle demonstrated in late preclinical studies or those in Phase I and beyond. For medical devices, companies must already have some in-human data to be considered. 

The firm seeks active involvement in portfolio management and typically holds board positions. Investment horizons generally range from 2–6 years, with exits often achieved through sales to larger companies positioned to complete commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment firm with offices in US, Europe, and Asia typically makes investments from $500K–1.5M, and the firm invests globally. The focus is on innovations aimed at preventing age-associated diseases, extending healthy lifespan, and improving human and animal performance. 
 

Within life sciences, the firm invests primarily in therapeutics and diagnostics, and also considers digital health opportunities. Traditional medical devices are generally out of scope. Areas of interest include gene therapy, telomere attrition, proteostasis, regenerative medicine, personalized diagnostics/biomarkers, preventative therapies, cognitive enhancement, and related fields. The firm is modality-agnostic and stage-opportunistic. 
 

The firm seeks companies with strong, protectable IP with clear ownership, supported by diverse management teams with proven track records, and technologies demonstrating validated proof of concept. Investments undergo a three-step diligence process: initial review, additional review focusing on differentiators such as IP and business model, and final review. The firm is open to leading, co-leading, or co-investing and leverages a strong syndication network of like-minded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm with a major presence in Europe invests in life science companies through various funds. The firm targets seed, venture, and growth-stage investments in European companies but also considers North American and Asian opportunities. Initial investment size ranges from €500K – 10M, preferentially in the form of straight equity. The firm is capable of leading or co-investing in financing rounds; however, for U.S. deals, the firm prefers a local investor to lead unless it is a later-stage round (i.e., B, C, etc.) and the prior round was led by a U.S. investor. The firm has greater flexibility for European-based companies and typically leads these rounds. The firm is currently in investing mode, actively seeking opportunities, with the average investment ranging from €3–5M. 
 

The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. Microbiome therapeutics and platforms are the primary interest, with willingness to invest as early as pre-clinical in this subsector. For other therapeutics, preferred phases of development are typically limited to pre-clinical investments into companies with a platform technology rather than those reliant on a single therapeutic asset. Medical technology and connected health companies are also evaluated, regardless of stage. 
 

The firm prefers to work with mature, experienced management teams but is open to all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of €50M. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A global venture capital investor builds, incubates, and invests in biotech companies. The firm invests from an evergreen fund and prefers to invest at company formation or seed stage, with the latest stage being Series A. Typical investments range from $1-5M, but larger tranched investments may be made in therapeutic opportunities. With offices across multiple global hubs, the firm invests worldwide. The firm can act as either a lead or a co-investor. 

The firm’s investment strategy focuses on disruptive therapeutics platform technologies and novel therapeutic modalities. 

The firm prefers to back teams with a strong track record but is also open to first-time entrepreneurs. At company formation, the firm not only provides funding for initial proof-of-concept studies, but also supports the assembly of the founding team and other essential business development activities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm founded in 2018 and based in the US actively invests in early-stage life science and healthcare companies with a focus on seed stage opportunities, investing up to $1M. The firm invests mostly in US, Europe, and Israel.  
 
The firm focuses on 2 areas: longevity and AI / future of healthcare. The firm is open to investing in therapeutics, medical devices, diagnostics, and digital health and will consider promising opportunities outside of these focus areas. 
 
The firm does not have specific management team requirements. The firm can lead or co-invest, and will typically seek board representation when leading investment rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital investor primarily makes angel investments in seed-stage companies and works hands-on with portfolio companies to facilitate regulatory approval and commercialization. Typical initial check size is in the $500–750K range, with tranche investments possible beyond this amount. The firm is open to global opportunities. 

The firm focuses on therapeutics companies in the early stages of drug discovery and development. Current areas of interest include CNS and neurodegenerative diseases, oncology, and pulmonary diseases pursued with novel approaches. While the firm works primarily with pre-clinical opportunities, it may consider other indications from time to time. 

The firm’s long-term strategy is to help companies progress toward Phase II readiness for pre-clinical assets. With broad expertise in regulatory and toxicology matters, the firm takes a hands-on approach to supporting portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology